% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kohle:1027019,
      author       = {Kohle, Felix and Wunderlich, Gilbert and Fink, Gereon R.
                      and Schroeter, Michael and Lehmann, Helmar C. and Schneider,
                      Christian},
      title        = {{R}ituximab in non-systemic vasculitic neuropathy: a
                      single-center experience},
      journal      = {Journal of neurology},
      volume       = {271},
      number       = {7},
      issn         = {0367-004X},
      address      = {Heidelberg},
      publisher    = {Springer},
      reportid     = {FZJ-2024-03585},
      pages        = {4406 - 4411},
      year         = {2024},
      note         = {Funding Open Access funding enabled and organized by
                      Projekt DEAL. FK was supported by the Cologne Clinician
                      Scientist Program (CCSP)/Faculty of Medicine/University of
                      Cologne. Funded by the Deutsche Forschungsgemeinschaft (DFG,
                      German Research Foundation) (Project No. 413543196).},
      abstract     = {Objectives This case series reports clinical features and
                      outcome of four patients with non-systemic vasculitic
                      neuropathy(NSVN) treated with the anti-CD20 agent
                      rituximab.Methods Clinical, electrophysiological and biopsy
                      data were retrospectively obtained and evaluated. Only
                      patients withpathological definite or probable NSVN were
                      included. Extensive clinical and laboratory work-up excluded
                      systemic vasculitis.Follow-up data for at least 12 months
                      and up to five years is provided. Outcome of the patients
                      was assessed usingthe MRC-Sum Score, Prineas Score and
                      Neurological Symptom Score.Results Two of four patients
                      treated with rituximab achieved disease remission and one
                      patient remained stable under anti-CD20 therapy after a
                      required treatment switch due to toxic side effects of
                      cyclophosphamide. One patient deteriorated underrituximab
                      induction. Rituximab was well tolerated in all
                      patients.Discussion Anti-CD20 therapy might be an
                      alternative in NSVN patients requiring further treatment
                      escalation or treatmentswitch due to side effects of
                      corticosteroids or cyclophosphamide.},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {5251 - Multilevel Brain Organization and Variability
                      (POF4-525) / DFG project 413543196 - Kölner Clinician
                      Scientist Programm (413543196)},
      pid          = {G:(DE-HGF)POF4-5251 / G:(GEPRIS)413543196},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {38656623},
      UT           = {WOS:001208272700002},
      doi          = {10.1007/s00415-024-12378-1},
      url          = {https://juser.fz-juelich.de/record/1027019},
}